

Edgar Filing: BIOMERICA INC - Form 10QSB/A

BIOMERICA INC
Form 10QSB/A
June 09, 2003

FORM 10-QSB/A
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

QUARTERLY REPORT UNDER SECTION 13 OR 15 (d)
OF THE SECURITIES EXCHANGE ACT OF 1934

For Quarter Ended February 28, 2003

Commission File No. 0-8765

BIOMERICA, INC.

(Exact name of registrant as specified in its charter)

Delaware

95-2645573

(State or other jurisdiction of
incorporation or organization)

(I.R.S. Employer
Identification No.)

1533 Monrovia Avenue, Newport Beach, California

92663

(Address of principal executive offices)

(Zip Code)

Registrant's telephone number including area code: (949) 645-2111

(Not applicable)

(Former name, former address and former fiscal year, if changed since last
report.)

Indicate by check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15 (d) of the Securities Exchange Act
of 1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to
such filing requirements for the past 90 days.

Yes X No

Indicate by check mark whether the Registrant is an accelerated filer (as
defined in Rule 12b-2 of the Exchange Act).

Yes No X

Edgar Filing: BIOMERICA INC - Form 10QSB/A

Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date: 5,260,142 shares of common stock as of April 9, 2003.

BIOMERICA, INC.

INDEX

PART I

Item 1. Financial Statements:

Consolidated Statements of Operations and Comprehensive Loss
(unaudited) - Nine Months and Three Months Ended
February 28, 2003 and 2002.....2 & 3

Consolidated Balance Sheet (unaudited) - February 28, 2003....4 & 5

Consolidated Statements of Cash Flows (unaudited)
Nine Months Ended February 28, 2003 and 2002.....6 & 7

Consolidated Statement of Changes in Shareholders' Equity
(unaudited) Nine Months Ended February 28, 2003.....8

Notes to Consolidated Financial Statements.....9-15

Item 2. Management's Discussion and Analysis of Financial Condition
and Selected Financial Data.....16-18

Item 3. Quantitative and Qualitative Disclosures about Market Risk.....18

Item 4. Procedures and controls..... 19

PART II Other Information.....19

Signatures.....20-24

PART I - FINANCIAL INFORMATION
SUMMARIZED FINANCIAL INFORMATION
ITEM 1. FINANCIAL STATEMENTS

BIOMERICA, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
AND COMPREHENSIVE LOSS (UNAUDITED)

Edgar Filing: BIOMERICA INC - Form 10QSB/A

	Nine Months Ended February 28,	
	2003	2002
Net sales	\$6,517,414	\$ 6,468,779
Cost of sales	4,515,017	4,384,346
Gross profit	\$2,002,397	2,084,433
Operating Expenses:		
Selling, general and administrative	2,113,020	2,322,817
Research and development	185,459	125,755
	2,298,479	2,448,572
Operating (loss) income from continuing operations...	(296,082)	(364,139)
Other Expense (income):		
Interest expense	25,273	26,087
Other (income) expense, net	(51,108)	(5,222)
	(25,835)	20,865
(Loss) income from continuing operations, before minority interest in net loss of consolidated subsidiaries	(270,247)	(385,004)
Minority interest in net (losses) profits of consolidated subsidiaries	31,209	(4,012)
(Loss) income from continuing operations, before income taxes	(301,456)	(380,992)
Income Tax Expense	3,018	1,600
Net (loss) income from continuing operations	(304,474)	(382,592)

2

BIOMERICA, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
AND COMPREHENSIVE LOSS (UNAUDITED)

	Nine Months Ended February 28,	
	2003	2002
Discontinued operations:		
Loss from discontinued operations, net	(40,022)	(78,774)

Edgar Filing: BIOMERICA INC - Form 10QSB/A

Net loss	(344,496)	(461,366)	
Other comprehensive loss, net of tax			
Unrealized loss on available-for-sale securities.....	(2,122)	(11,001)	
	-----	-----	-----
Comprehensive loss	\$ (346,618)	\$ (472,367)	\$
	=====	=====	=====
Basic net loss per common share:			
Net income (loss) from continuing operations ...	\$ (.06)	\$ (.08)	\$
Net loss from discontinued operations	(.01)	(.01)	
	-----	-----	-----
Basic net loss per common share	\$ (.07)	\$ (.09)	\$
	=====	=====	=====
Diluted net loss per common share:			
Net income (loss) from continuing operations	\$ (.06)	\$ (.08)	\$
Net income (loss) from discontinued operations ...	(.01)	(.01)	
	-----	-----	-----
Diluted net loss per common share	\$ (.07)	\$ (.09)	\$
	=====	=====	=====
Weighted average number of common and common equivalent shares:			
Basic and diluted	5,224,867	5,065,534	5,
	=====	=====	=====

The accompanying notes are an integral part of these statements.

3

BIOMERICA, INC.

CONSOLIDATED BALANCE SHEET (UNAUDITED)

	February 28, 2003

Assets	
Current Assets	
Cash and cash equivalents	\$ 580,147
Available-for-sale securities	410
Accounts receivable, less allowance for doubtful accounts of \$194,492..	1,538,485
Inventory, net	2,504,772
Notes receivable	2,419
Prepaid expenses and other	80,542

Total Current Assets	4,706,775

Edgar Filing: BIOMERICA INC - Form 10QSB/A

Inventory, non-current	17,000
Property and Equipment, net of accumulated depreciation and amortization...	264,917
Intangible assets, net of accumulated amortization	85,282
Other Assets	39,197

	\$5,113,171
	=====

The accompanying notes are an integral part of these statements.

4

BIOMERICA, INC.

CONSOLIDATED BALANCE SHEET (UNAUDITED), CONTINUED

	February 28, 2003

Liabilities and Shareholders' Equity	
Current Liabilities	
Line of credit	\$ 478
Accounts payable and accrued liabilities	956,056
Accrued compensation	325,241
Shareholder loan.....	328,250
Net liabilities from discontinued operations	363,914

Total Current Liabilities	1,973,939
Minority interest	2,134,081

Shareholders' Equity	
Unrealized loss on available-for-sale of securities.....	(22,359)
Common stock, \$0.08 par value authorized 25,000,000 shares, subscribed or issued and outstanding 5,478,324	420,810
Common stock subscribed.....	66,600
Additional paid-in-capital	17,073,173
Accumulated deficit	(16,533,073)

Total Shareholders' Equity	1,005,151

Total Liabilities and Shareholders' Equity	\$ 5,113,171
	=====

The accompanying notes are an integral part of these statements.

Edgar Filing: BIOMERICA INC - Form 10QSB/A

5

BIOMERICA, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)

NINE MONTHS ENDED FEBRUARY 28, 2003 AND 2002

	2003	2002
	-----	-----
Cash flows from operating activities:		
Net loss from continuing operations	\$(304,474)	\$(382,592)
Adjustments to reconcile net loss to net cash (used in) operating activities:		
Depreciation and amortization	106,138	149,211
Realized gain on sale of available for-sale securities..	--	(10,026)
Minority interest in net income (loss) of consolidated subsidiaries	31,209	(4,012)
Common stock issued for services rendered	67,517	61,886
Provision for losses on accounts receivable ...	(1,960)	(4,905)
Warrants and options issued for services rendered	48,546	64,560
Changes in current assets and liabilities:		
Accounts Receivable	(32,181)	(112,381)
Inventories	414,240	(58,580)
Prepaid expenses and other current assets ...	41,932	(23,209)
Accounts payable and other accrued liabilities	49,866	138,214
Accrued compensation	17,259	51,482
	-----	-----
Net cash provided by (used in) operating activities	438,092	(130,352)
	-----	-----
Cash flows from investing activities:		
Sale of available for-sale securities	--	39,116
Increase in notes receivable	--	--
Purchases of property and equipment	(90,328)	(8,341)
Other assets	(3,651)	(1,971)
Purchases of intangible assets	(21,987)	(10,591)
	-----	-----
Net cash (used in) provided by investing activities	(115,966)	18,213
	-----	-----
Cash flows from financing activities:		
Issuance of shares by subsidiary	17,980	--
Proceeds from sale of common stock subscribed	25,000	--
Private placement net of offering costs	--	4,400
Exercise of stock options	--	1,128
(Decrease) increase in line of credit	(65,191)	(22,815)
Increase in shareholder loan	(46,750)	215,000
	-----	-----

Edgar Filing: BIOMERICA INC - Form 10QSB/A

6

BIOMERICA, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)
(CONTINUED)

NINE MONTHS ENDED FEBRUARY 28, 2003 AND 2002

	2003	2002
	-----	-----
Net cash (used in) provided by financing activities	(68,961)	197,713
Net cash used in discontinued operations	(2,295)	(103,001)
Net increase (decrease) in cash	250,870	(17,427)
and cash equivalents		
Cash at beginning of period	329,277	136,299
Cash at end of period	\$ 580,147	\$ 118,872
	=====	=====

The accompanying notes are an integral part of these statements.

7

BIOMERICA, INC.

CONSOLIDATED STATEMENT OF CHANGES IN SHAREHOLDERS' EQUITY (UNAUDITED)
FOR THE NINE MONTHS ENDED FEBRUARY 28, 2003

	Common Stock			Common Stock Subscribed		Accumul Other Compreh Loss
	Number of Shares	Amount	Additional Paid-in Capital	Shares	Amount	
	-----	-----	-----	-----	-----	-----
Balances at May 31, 2002	5,172,364	\$ 413,788	\$16,981,982	28,333	\$ 23,750	\$ (20,
Compensation expense in connection with options and warrants granted	--	--	48,546	--	--	
Shares subscribed for cash	--	--	--	100,000	25,000	
Change in unrealized						

Edgar Filing: BIOMERICA INC - Form 10QSB/A

gain on available for sale securities	--	--	--	--	--	(2,
Common stock subscribed for services rendered	--	--	--	11,667	5,250	
Common stock for Services rendered	67,778	5,422	35,245	--	--	
Common stock issued	20,000	1,600	7,400	(20,000)	(9,000)	
Common stock subscribed For services	--	--	--	98,182	21,600	
Net loss	--	--	--	--	--	
Balances at February 28, 2003	5,260,142	\$ 420,810	\$17,073,173	218,182	\$ 66,600	\$ (22,

8

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

February 28, 2003

- (1) Reference is made to Note 2 of the Notes to Consolidated Financial Statements contained in the Company's Annual Report on Form 10-KSB for the fiscal year ended May 31, 2002, for a summary of significant accounting policies utilized by the Company.
- (2) The information set forth in these consolidated statements is unaudited and may be subject to normal year-end adjustments. The information reflects all adjustments which, in the opinion of management, are necessary to present a fair statement of results of operations of Biomerica, Inc., for the periods indicated. It does not include all information and footnotes necessary for a fair presentation of financial position, results of operations, and cash flow in conformity with generally accepted accounting principles.
- (3) Consolidated results of operations for the interim periods covered by this Report may not necessarily be indicative of results of operations for the full fiscal year.
- (4) Reference is made to Note 3 of the Notes to Consolidated Financial Statements contained in the Company's Annual Report on Form 10-KSB for the fiscal year ended May 31, 2002, for a description of the investments in affiliates and consolidated subsidiaries.
- (5) Reference is made to Notes 5 & 10 of the Notes to Consolidated Financial Statements contained in the Company's Annual Report on Form 10-KSB for the fiscal year ended May 31, 2002, for information on commitments and contingencies.
- (6) Aggregate cost of available-for-sale securities exceeded aggregate market value by approximately \$22,359 at February 28, 2003.
- (7) Earnings Per Share

Edgar Filing: BIOMERICA INC - Form 10QSB/A

In February 1997, the Financial Accounting Standards Board ("FASB") issued Statement of Financial Accounting Standards (SFAS) No. 128, EARNINGS PER SHARE ("EPS"). SFAS No. 128 requires dual presentation of basic EPS and diluted EPS on the face of all income statements issued after December 15, 1997 for all entities with complex capital structures. Basic EPS is computed as net income divided by the weighted average number of common shares outstanding for the period. Diluted EPS reflects the potential dilution that could occur from common shares issuable through stock options, warrants and other convertible securities. For all periods presented, no common stock equivalents have been included in the computation of diluted earnings per share as they were determined to be anti-dilutive.

The following table illustrates the required disclosure of the reconciliation of the numerators and denominators of the basic and diluted EPS computations.

9

	For the Nine Months Ended February 28, 2003		
	Income (Numerator)	Shares (Denominator)	Per Share Amount
Basic EPS -			
(Loss) gain from continuing operations	\$ (304,474)	--	\$ (.)
(Loss) gain from discontinued operations	(40,022)	5,224,867	(.)
Diluted EPS -			
Loss attributable to common share- holders plus assumed conversions	\$ (344,496)	5,224,867	\$ (.)
	=====	=====	=====
	For the Nine Months Ended February 28, 2002		
	Income (Numerator)	Shares (Denominator)	Per Share Amount
Basic EPS -			
Loss from continuing operations	\$ (382,592)	--	\$ (.)
Loss from discontinued operations	(78,774)	5,065,534	(.)
Diluted EPS -			
Loss attributable to common share- holders plus assumed conversions	\$ (461,366)	5,065,534	\$ (.)
	=====	=====	=====

10

For the Three Months Ended February 28, 2003

Income Shares Per Share

Edgar Filing: BIOMERICA INC - Form 10QSB/A

	(Numerator)	(Denominator)	Amount
	-----	-----	-----
Basic EPS -			
Gain (loss) from continuing operations	\$ (24,644)		\$ (.)
Gain from discontinued operations	(1,491)	5,258,475	(.)
	-----	-----	-----
Diluted EPS -			
Loss attributable to common share- holders plus assumed conversions	\$ (26,135)	5,258,475	\$ (.)
	=====	=====	=====
For the Three Months Ended February 28, 2002			
	Income (Numerator)	Shares (Denominator)	Per Share Amount
	-----	-----	-----
Basic EPS -			
Income from continuing operations	\$ 24,166		\$.)
Loss from discontinued operations	(39,533)	5,120,654	(.)
	-----	-----	-----
Diluted EPS -			
Loss attributable to common share- holders plus assumed conversions	\$ (15,367)	5,120,654	\$ (.)
	=====	=====	=====

The computation of diluted loss per share excludes the effect of incremental common shares attributable to the exercise of outstanding common stock options and warrants because their effect was antidilutive due to losses incurred by the Company.

As of February 28, 2003, there was a total of 2,916,595 potentially dilutive shares of common stock.

(8) Recent Accounting Pronouncements

In July 2001, the FASB issued Statement of Financial Accounting Standards No. 142 ("SFAS 142"), "Goodwill And Intangible Assets", which revises the accounting for purchased goodwill and intangible assets. Under SFAS 142, goodwill and intangible assets with indefinite lives will no longer be amortized and will be tested for impairment annually. SFAS 142 is effective for fiscal years beginning after December 15, 2001, with earlier adoption permitted. The Company adopted SFAS 142 on June 1, 2002. SFAS 142 did not have a material impact on the Company's financial position or results of operations as a result of the future adoption of SFAS 142.

In August 2001, the FASB issued Statement of Financial Accounting Standards FAS No. 143 ("SFAS 143"), "Accounting for Asset Retirement Obligations." This statement addresses financial accounting and reporting for obligations associated with the retirement of tangible long-lived assets and the associated asset retirement costs. It applies to all entities and legal obligations associated with the retirement of long-lived assets that result from the acquisition, construction, development and/or normal operations of long-lived

Edgar Filing: BIOMERICA INC - Form 10QSB/A

assets, except for certain obligations of leases. This statement is effective for financial statements issued for fiscal years beginning after June 15, 2002. Management has not yet determined the impact of the adoption of SFAS No. 143 on the Company's financial position or results of operations.

In October 2001, FASB issued Statement of Financial Accounting

Standards No. 144 ("SFAS 144"), "Accounting for the Impairment or Disposal of Long-Lived Assets," or SFAS No. 144 which requires that those long-lived assets be measured at the lower of carrying amount or fair value less cost to sell, whether reported in continuing operations or in discontinued operations. Therefore, discontinued operations will no longer be measured at net realizable value or include amounts for operating losses that have not yet occurred. SFAS No. 144 is effective for financial statements issued for fiscal years beginning after December 15, 2001 and, generally, is to be applied prospectively. The adoption of SFAS 144 did not have a material impact on the Company's financial position or results of operations.

In April 2002, the FASB issued Statement of Financial Accounting Standards No. 145 ("SFAS 145"), "Recission of FASB Statements No. 4 and 64, Amendment of FASB Statement No. 13, and Technical Corrections," to update, clarify and simplify existing accounting pronouncements. FASB Statement No. 4, which required all gains and losses from debt extinguishments to be aggregated and, if material, classified as an extraordinary item, net of related tax effect, was rescinded. Consequently, FASB Statement No. 64, which amended FASB Statement No. 4, was rescinded because it was no longer necessary. The adoption of SFAS 145 did not have a material impact on the Company's financial position or results of operations.

In June 2002, the FASB issued Statement of Financial Accounting Standards No. 146, "Accounting for Costs Associated with Exit or Disposal Activities." SFAS 146 addresses accounting and reporting for costs associated with exit or disposal activities and nullifies Emerging Issues Task Force Issue No. 94-3, "Liability Recognition for Certain Employee Termination Benefits and Other Costs to Exit an Activity (Including Certain Costs Incurred in a Restructuring)." "SFAS No. 146 requires that a liability for a cost associated with an exit or disposal activity be recognized and measured initially at fair value when the liability is incurred. SFAS No. 146 is effective for exit or disposal activities that are initiated after December 31, 2002, with early application encouraged. We do not expect the adoption of this statement to have a material effect on our financial statements.

In December 2002, the FASB issued SFAS No. 148 "Accounting for Stock-Based Compensation, Transition and Disclosure, an amendment of FASB Statement No. 123." SFAS No. 148 provides alternative methods of transition for an entity that voluntarily changes to the fair value based method of accounting for stock-based employee compensation. It also amends the disclosure provisions of SFAS No. 123 to require prominent disclosure about the effects on reported net income of an entity's accounting policy decisions with respect to stock-based employee compensation. Finally, this Statement amends APB Opinion No. 28, "Interim Financial Reporting," to require disclosure about those effects in the interim financial information. The amendments to SFAS No. 123 that provide alternative methods of transition for an entity that voluntarily changes to the fair value based method of accounting for stock-based employee compensation are effective for financial

Edgar Filing: BIOMERICA INC - Form 10QSB/A

statements for fiscal years ending after December 15, 2002. The amendment to SFAS No. 123 relating to disclosure and the amendment to Opinion 28 is effective for financial reports containing condensed financial statements for interim periods beginning after December 15, 2002. Early application is encouraged. Management currently believes that the adoption of SFAS No. 148 will not have a material impact on the financial statements.

- (9) Financial information about foreign and domestic operations and export sales is as follows:

	For the Nine Months Ended	
	2/28/03	2/28/02
	-----	-----
Revenues from sales to unaffiliated customers:		
United States	\$3,453,000	\$3,240,000
Asia	166,000	143,000
Europe	1,614,000	1,761,000
South America	283,000	372,000
Oceania	325,000	284,000
Other	676,000	669,000
	-----	-----
	\$6,517,000	\$6,469,000
	=====	=====

No other geographic concentrations exist where net sales exceed 10% of total net sales.

- (10) On January 15, 2002, the Company received a Nasdaq Staff Determination indicating that the Company failed to comply with the net tangible assets or shareholders' equity requirements for continued listing set forth in Marketplace Rule 4310(c)(2)(B), and that its securities were, therefore, subject to delisting from the Nasdaq SmallCap Market effective January 23, 2002. The Company requested a hearing before a Nasdaq Listing Qualifications Panel to review the Staff Determination. The request for a hearing stayed the delisting of the Company's securities pending the Panel's decision. On February 21, 2002 the hearing took place. In response to the hearing, on March 25, 2002, the Company received a Nasdaq Staff Determination letter staying their decision with respect to the continued listing of the Company's

securities. The Panel determined to continue the listing of the Company's securities on the Nasdaq SmallCap Market via an exception from the net tangible assets requirement. While the Company failed to meet this requirement, the Company was granted a temporary exception from the standard subject to the Company meeting certain conditions by specified deadlines.

The Company was unable to satisfy the conditions within the deadlines established by the Panel. Pursuant to a decision by the Nasdaq Listing Qualifications Panel, the Company's common stock was

Edgar Filing: BIOMERICA INC - Form 10QSB/A

delisted from the Nasdaq Stock Market effective June 20, 2002, for failure to comply with the net tangible assets or shareholders' equity requirements as set forth in Marketplace Rule 4310(c)(2)(B). The Company's securities were immediately eligible to trade on the OTC Bulletin Board and are traded under the symbol BMRA.OB.

On February 14, 2002, the Company received a Nasdaq Staff Determination letter indicating that the Company failed to comply with the minimum \$1.00 per share requirement for continued inclusion of its common stock under Marketplace Rule 4310(c)(4), and therefore is subject to delisting from the Nasdaq SmallCap Market. In accordance with Marketplace Rule 4310(c)(8)(D), the Company would have been provided 180 calendar days, or until August 13, 2002, to regain compliance. However, prior to that time, the Company was delisted according to the above mentioned reasons.

Shares traded on the OTC Bulletin Board are not as liquid as those traded on the Nasdaq National market or the Nasdaq SmallCap market.

The 1-for-3 reverse stock split approved by shareholders at the 2001 shareholders' meeting for the purpose of increasing the price per share of the common stock will not be implemented.

- (11) The Company has suffered substantial recurring losses from operations over the past several years. The Company has funded its operations through debt and equity financings, and may have to do so in the future. Allergy Immuno Technologies operations were discontinued in May 2002. The Company plans to reduce operating costs through certain cost reduction efforts and concentrate on its core business in Lancer and Biomerica to increase sales. There can be no assurances that the Company will be able to become profitable, generate positive cash flows from operations or obtain the necessary equity or debt financing to fund operations in the future.

As of February 28, 2003, the Company had cash and available-for-sale securities in the amount of \$580,557 and working capital of \$2,732,836. Cash and working capital totaling \$568,461 and \$2,897,745, respectively, relates to the Lancer subsidiary. Lancer's line of credit restricts Biomerica's ability to draw on Lancer's resources and, as such, said cash, working capital and equity are not available to Biomerica. Biomerica, Inc. and subsidiaries, are expected to fund their operations for at least the next twelve months through their existing available financing, working capital, and its shareholder line of credit.

During the nine months ended February 28, 2003, the Company operations provided cash of \$438,092. This compares to cash used in operations of \$130,352 in the same period in the prior fiscal year. Cash used by financing activities was \$68,961, which resulted from the payment on the line of credit at Lancer of \$65,191 and payment of the shareholder loan at Biomerica of \$46,750, which were offset by proceeds from sale of common stock subscribed of \$25,000.

- (12) At February 28, 2003, Lancer had a \$400,000 revolving line of credit with GE Capital Healthcare Financial Services, which expires October 24, 2003. Borrowings are made at prime plus 2.00%, in no event less than 8%, (8.0% at February 28, 2003) and are limited to 80% of accounts receivable less than 90 days old with a liquidity factor of 94%. The outstanding balance at February 28, 2003 was \$478 and the unused portion available under the line of credit at February 28, 2003 was approximately \$310,000.

Edgar Filing: BIOMERICA INC - Form 10QSB/A

The line of credit is collateralized by substantially all the assets of Lancer, including inventories, receivables and equipment. The lending agreement requires, among other things, that Lancer maintain a tangible net worth of \$2,100,000 and that receivables payments be sent to a controlled lockbox. In addition to interest, a management fee of .0425% on the average monthly unused portion available is required. Lancer is not required to maintain compensating balances in connection with this lending agreement. Lancer's line of credit restricts Biomerica's ability to draw on Lancer's resources and, as such, said cash, working capital and equity are not available to Biomerica.

- (13) Biomerica, Inc. entered into a line of credit agreement on September 12, 2000 with Janet Moore, an officer and director whereby she will loan to the Company, as needed, up to \$500,000 for working capital needs. The line of credit bears interest at 8%, is secured by Biomerica accounts receivable and inventory and expires September 12, 2003. The unused portion of the line of credit at February 28, 2003, was \$181,750. Additionally, the Company received a \$10,000 unsecured loan from a different shareholder. Such amount is included in shareholder loan in the accompanying consolidated financial statements.

13

- (14) In July 2002, 67,778 shares of Biomerica restricted common stock (at \$0.60 per share), were approved for issuance in payment of accrued salary for two officers/directors. In connection with this issuance, Biomerica recorded compensation expense of \$40,667, the fair market value of the stock at the time of issuance. During the nine months ended February 28, 2003, 11,667 shares of Biomerica's restricted common stock value at \$5,250 were earned in payment to its Chief Executive Officer for certain management services.
- (15) On September 24, 2002, the Company agreed to issue 20,000 options at the then fair market value of \$.30 per share to employees. These options will vest over four years. No compensation expense was recorded for this transaction.
- (16) The Company agreed to a bonus plan for employees of 10% to 20% of the profit of the diagnostics' division for the year ending May 31, 2003. The board will determine distribution percentages of profit from diagnostics' continuing operations for any bonuses based on audited financials as of May 31, 2003. All permanent employees, including executive officers, will be included in the plan. As of February 28, 2003, there has been no accrual since the plan is based on profits and year-to-date there has not been a profit in the diagnostics' division.
- (17) On April 10, 2002, the Company filed a Form S-4 for the proposed registration of between 488,200 and 984,274 shares of Biomerica common stock. The shares were to be issued for the purchase of the assets of the subsidiary Lancer Orthodontics, Inc. Due to market conditions, both boards of directors have agreed not to proceed with the proposed purchase and in July 2002 Biomerica requested that the registration statement be withdrawn.
- (18) In June 2002 the Company signed a distribution agreement with a company in Japan for the distribution of certain kits. The Company

Edgar Filing: BIOMERICA INC - Form 10QSB/A

received a deposit of \$35,000 in the month of June 2002 related to this agreement. The Company has shipped \$2,000 worth of product to date. The balance of \$33,000 is recorded in other liabilities.

- (19) On September 24, 2002, the Board of Directors approved the grant of a stock option for 7,000 shares of Biomerica common stock at an exercise price of \$.30 per share to an outside consultant. The Company also entered into a one year consulting agreement with this consultant whereby the consultant will help with business development and other services during that period and upon achievement of certain milestones has the opportunity to be granted two additional 7,000 share options at a fifteen percent discount to market.
 - (20) On November 12, 2002, the Board of Directors approved the issuance of 98,182 shares of restricted common stock at the price of \$.22 per share in lieu of \$21,600 in accrued salary to two officers/directors. These shares were issued in March 2003.
 - (21) During the nine months ended February 28, 2003, \$48,546 was recorded as amortization expense for previously issued warrants and options.
 - (22) Lancer Orthodontics, Inc. granted non-qualified options to the Chief Executive Officer to purchase 113,000 shares of common stock at \$.30. These options were granted on December 1, 2001 and are exercisable at the rate of one-third per year and have a term of five years.
 - (23) For the nine months ended February 28, 2003, other income of \$62,655 was realized from the insurance claim settlement of \$144,413 for the theft of inventory at the Lancer Orthodontics, Inc.'s Mexicali facility, less \$81,758 insurance claim receivable valued at cost.
 - (24) Lancer Orthodontics, Inc. issued non-qualified stock options to three employees totaling 70,000 shares during the quarter ended November 30, 2002. The shares are at \$.28 per share and expire in five years. During the quarter ended February 28, 2003, non-qualified stock options for 70,000 options were granted to various employees.
 - (25) During this quarter Lancer Orthodontics approved the issuance of 53,846 shares of restricted common stock to the chief executive officer. The shares were in payment of accrued salary of \$14,000.
 - (26) In October 2002 the Company signed an agreement with Medical Device Safety Service GmbH ("MDDS") wherein MDSS will act as the Company's Authorized Representative for the purpose of obtaining a CE-Mark in Europe.
 - (27) During the quarter ended February 28, 2003, \$25,000 was received for the purchase of 100,000 shares of restricted common stock with detachable warrants to purchase 100,000 shares of restricted common stock at \$.25 per share. This was recorded as common stock subscribed since at the end of the quarter the shares had not yet been issued.
- 14
- (28) In November 2002 the Company signed a distribution agreement for its EZ Detect product with a company in Spain.
 - (29) In January 2003 the Company signed a distribution agreement for its Allerquant 90G IgG ELISA kit with a company in Spain.

Edgar Filing: BIOMERICA INC - Form 10QSB/A

(30) Reportable business segments for the nine months and quarter ended February 28, 2003 and 2002 are as follows:

	Nine Months Ended February 28, 2003		Three Months Ended February 2003	
	-----	-----	-----	-----
Domestic sales:				
Orthodontic products	\$ 2,323,000	\$ 2,273,000	\$ 756,000	\$
Medical diagnostic products	1,130,000	967,000	335,000	
Foreign sales:				
Orthodontic products	\$ 1,975,000	\$ 2,232,000	\$ 752,000	\$
Medical diagnostic products	1,089,000	997,000	448,000	
Net sales:				
Orthodontics products	\$ 4,298,000	\$ 4,505,000	\$ 1,508,000	\$ 1,
Medical diagnostic products	\$ 2,219,000	1,964,000	783,000	
Total	\$ 6,517,000	\$ 6,469,000	\$ 2,291,000	\$ 2,
Operating profit (loss):				
Orthodontic products	\$ 1,000	\$ 39,000	\$ 22,000	\$
Medical diagnostic products	\$ (297,000)	\$ (403,000)	(24,000)	
Total	\$ (296,000)	\$ (364,000)	\$ (2,000)	\$
Operating loss from discontinued Segment:				
AIT	\$ --	\$ (66,883)	\$ --	\$
ReadyScript	(40,022)	\$ (11,891)	(1,491)	
Total	(40,022)	(78,774)	(1,491)	
Depreciation and amortization Expense:				
Orthodontic products	\$ 64,210	\$ 80,568	\$ 15,976	\$
Medical diagnostic products	41,928	68,643	17,512	
Total	\$ 106,138	\$ 149,211	\$ 33,488	\$
		As of February 28,		
		2003	2002	
		-----	-----	
Domestic long-lived assets:				
Orthodontic products	\$ 92,330	\$ 24,056		
Medical diagnostic products	156,248	193,501		
Total	\$ 248,578	\$ 217,557		
Foreign long-lived assets:				
Orthodontic products	\$ 15,668	28,946		
Medical diagnostic products	3,571	0		

Edgar Filing: BIOMERICA INC - Form 10QSB/A

Total	\$ 267,817	\$ 246,503
Total assets:		
Orthodontic products	\$3,568,000	\$3,628,520
Medical diagnostic products	1,545,000	1,731,550
Total	\$5,113,000	\$5,360,070

15

MANAGEMENT'S DISCUSSION AND ANALYSIS OF
FINANCIAL CONDITION AND SELECTED FINANCIAL DATA

CERTAIN INFORMATION CONTAINED HEREIN (AS WELL AS INFORMATION INCLUDED IN ORAL STATEMENTS OR OTHER WRITTEN STATEMENTS MADE OR TO BE MADE BY BIOMERICA) CONTAINS STATEMENTS THAT ARE FORWARD-LOOKING, SUCH AS STATEMENTS RELATING TO ANTICIPATED FUTURE REVENUES OF THE COMPANY AND SUCCESS OR CURRENT PRODUCT OFFERINGS. SUCH FORWARD-LOOKING INFORMATION INVOLVES IMPORTANT RISKS AND UNCERTAINTIES THAT COULD SIGNIFICANTLY AFFECT ANTICIPATED RESULTS IN THE FUTURE, AND ACCORDINGLY, SUCH RESULTS MAY DIFFER MATERIALLY FROM THOSE EXPRESSED IN ANY FORWARD-LOOKING STATEMENTS MADE BY OR ON BEHALF OF BIOMERICA. THE POTENTIAL RISKS AND UNCERTAINTIES INCLUDE, AMONG OTHERS, FLUCTUATIONS IN THE COMPANY'S OPERATING RESULTS DUE TO ITS NEW BUSINESS MODEL AND EXPANSION PLANS AND THE COMPETITIVE ENVIRONMENT IN WHICH THE COMPANY WILL BE DOING BUSINESS. THESE RISKS AND UNCERTAINTIES ALSO INCLUDE THE SUCCESS OF THE COMPANY IN RAISING NEEDED CAPITAL, THE CONTINUAL DEMAND FOR THE COMPANY'S PRODUCTS, COMPETITIVE AND ECONOMIC FACTORS OF THE MARKETPLACE, AVAILABILITY OF RAW MATERIALS, THE EFFECTS OF TERRORISM, HEALTH CARE REGULATIONS AND THE STATE OF THE ECONOMY. READERS ARE CAUTIONED NOT TO PLACE UNDUE RELIANCE ON THESE FORWARD-LOOKING STATEMENTS, WHICH SPEAK ONLY AS OF THE DATE HEREOF, AND THE COMPANY UNDERTAKES NO OBLIGATION TO UPDATE THESE FORWARD-LOOKING STATEMENTS.

RESULTS OF OPERATIONS

Consolidated net sales for Biomerica were \$6,517,414 for the nine months ended February 28, 2003 as compared to \$6,468,779 for the same period in the previous year. This represents an increase of \$48,635, or .7% (this includes a decrease at Lancer of \$206,823 and an increase at Biomerica of \$255,458). Sales at Lancer decreased primarily due to a decrease in foreign sales, particularly in Europe and South America. The increase in sales at Biomerica was due to general overall increase in diagnostic sales as well as a large colorectal screening program in the first quarter. For the quarter then ended sales were \$2,291,377 as compared to \$2,306,135 for the same period in the prior fiscal year. This represents a decrease of \$14,758, or ..6% (this includes an increase of \$66,894 at Lancer and a decrease at Biomerica of \$81,652.). The decrease at Biomerica was due to no colorectal screening program in this fiscal quarter.

Cost of sales for the nine months increased as a percentage of sales from 67.8% to 69.3%. Cost of sales for the three months then ended increased from 64.5% to 68.2% primarily because of increased sales of lower margin products at the diagnostics' division. For the nine months Lancer had a decrease in cost of sales of \$1,431, however, this resulted in an increase from 68.0% to 71.2% of Lancer's sales and for the quarter an increase of \$115,770, or from 67.2% to 71.9% of Lancer's sales. Lancer had an increase

Edgar Filing: BIOMERICA INC - Form 10QSB/A

in the cost of goods due to increased production costs. Biomerica had an increase of \$132,102, or from 67.2% to 65.5% of sales for the nine months due to the addition of manufacturing personnel and a decrease of \$40,628 for the three months, or from 67.2% to 65.5% of sales.

Selling, general and administrative costs decreased by \$209,798, or 9.0% for the nine months. For the three months then ended these costs decreased by \$73,628, or 10.0%. Of these decreases, Lancer had a decrease for the nine months of \$233,732 and for the three months of \$38,646. The decrease at Lancer was attributable to decreased labor and travel costs of terminated marketing support personnel, whose responsibilities were assumed by existing general and administrative personnel. Biomerica had an increase of \$23,934 for the nine months and a decrease of \$34,980 for the three months. The increase at Biomerica for the nine months was attributable to higher selling and marketing expenses, primarily related to payroll. The decrease for the quarter was due to lower commissions.

Research and development increased by \$59,704, or 47.5% for the nine months. For the three months these costs increased by \$38,148, or 102.8%. The increases were primarily due to hiring of additional personnel at Biomerica and resumption of product development at Lancer. For the nine months Lancer had an increase of 66,024 and for the three months an increase of \$34,842. For the nine months Biomerica had a decrease of \$6,320 and for the three months an increase of \$3,306.

Interest expense decreased by \$814 for the nine months and \$3,261 for the three months compared to the previous year due to borrowings on the line of credit at Biomerica and decreased borrowing at Lancer. For the nine months Lancer had a decrease of \$9,289 and for the three months a decrease of \$5,410. Biomerica had an increase of \$8,475 for the nine months and an increase of \$2,149 for the three months.

At February 28, 2003, the Company retained a 31.1% interest in Lancer Orthodontics. The Company maintains a 53.76% indirect voting control over Lancer Orthodontics via agreements with certain shareholders. The Company also retains an 88.9% interest in ReadyScript. Please refer to Note 3 in the Notes to the Consolidated Financial Statements in the report on Form 10-KSB for the year ended May 31, 2002, for a more in-depth discussion of subsidiaries.

Aside from general macroeconomic downturns, the additional material factors that could affect future financial results include, but are not limited to: terrorist attacks and the impact of such events; diminished access to raw materials that directly enter into our manufacturing process; shipping labor disruption or other major degradation of the ability to ship out products to end users; inability to successfully control our margins which are affected by many factors including competition and product mix; protracted shutdown of the U.S. border due to escalation of terrorist or counter terrorist activity; the operating and financial covenants contained in our credit line and Lancer's which could limit our operating flexibility; any changes in our business relationships with international distributors or the economic climate they operate in; any event that has a material adverse impact on our foreign manufacturing operations may adversely affect our operations as a whole; failure to manage the future expansion of our business could have a material adverse affect on our revenues and profitability; possible costs in complying with government regulations and the delays in receiving required regulatory approvals or the enactment of

Edgar Filing: BIOMERICA INC - Form 10QSB/A

new, adverse regulations or regulatory requirements; numerous competitors, some of which have substantially greater financial and other resources than we do; potential claims and litigation brought by patients or dental or medical professionals alleging harm caused by the use of or exposure to our products; quarterly variations in operating results caused by a number of factors, including business and industry conditions and other factors beyond our control. All these factors make it difficult to predict operating results for any particular period.

LIQUIDITY AND CAPITAL RESOURCES

As of February 28, 2003, the Company had cash and available-for-sale securities in the amount of \$580,557 and working capital of \$2,732,836. Cash and working capital totaling \$568,461 and \$2,897,745, respectively, relates to the Lancer subsidiary. Lancer's line of credit restricts Biomerica's ability to draw on Lancer's resources and, as such, said cash, working capital and equity are not available to Biomerica. Biomerica, Inc. and its subsidiaries, are expected to fund their operations for at least the next twelve months through their existing available financing, working capital, and its shareholder line of credit.

The Company has suffered substantial recurring losses from operations over the past several years. The Company has funded its operations through debt and equity financings, and may have to do so in the future. Allergy Immuno Technologies' operations, were discontinued May 2002. The Company plans to reduce operating costs through certain cost reduction efforts and concentrate on its core business in Lancer and Biomerica to increase sales. There can be no assurances that the Company will be able to become profitable, generate positive cash flow from operations or obtain the necessary equity or debt financing to fund operations in the future.

During the nine months ended February 28, 2003, the Company's operations provided cash of \$438,092. This compares to net cash used by operations of \$130,352 in the same period in the prior fiscal year. Cash used in investing activities was \$115,966 as compared to cash provided by investing activities in the prior year of \$18,213. This resulted from the purchases of property and equipment, other assets and intangible assets. Cash used by financing activities was \$68,961, which resulted from the payment on the line of credit at Lancer of \$65,192 and payment on the shareholder loans at Biomerica of \$46,750. The interest of 8% per annum due on the loans at Biomerica is being accrued and has not been paid to date. As of February 28, 2003 there was \$39,672 in accrued interest due.

On January 15, 2002, the Company received a Nasdaq Staff Determination indicating that the Company failed to comply with the net tangible assets or shareholders' equity requirements for continued listing set forth in Marketplace Rule 4310(c)(2)(B), and that its securities are, therefore, subject to delisting from the Nasdaq SmallCap Market effective January 23, 2002. The Company requested a hearing before a Nasdaq Listing Qualifications Panel to review the Staff Determination. The request for a hearing stayed the delisting of the Company's securities pending the Panel's decision. On February 21, 2002 the hearing took place. On March 25, 2002, the Company received a Nasdaq Staff Determination letter stating their decision with respect to the continued listing of the Company's securities. The Panel determined to continue the listing of the Company's securities on the Nasdaq SmallCap market via an exception from the net tangible assets requirement. While the Company failed to meet this requirement, the Company was granted a temporary exception from the standard subject to the Company meeting certain conditions by specified deadlines.

The Company was unable to satisfy the conditions within the deadlines established by the Panel. Pursuant to a decision by the Nasdaq

Edgar Filing: BIOMERICA INC - Form 10QSB/A

Listing Qualifications Panel, the Company's common stock was delisted from the Nasdaq Stock Market effective June 20, 2002, for failure to comply with the net tangible assets or shareholders' equity requirements as set forth in Marketplace Rule 4310(c)(2)(B). The Company's securities were immediately eligible to trade on the OTC Bulletin Board and are traded under the symbol BMRA.OB.

On February 14, 2002, the Company received a Nasdaq Staff Determination letter indicating that the Company failed to comply with the minimum \$1.00 per share requirement for continued inclusion of its common stock under Marketplace Rule 4310(c)(4), and therefore was subject to delisting from the Nasdaq SmallCap Market. The Company would have been provided 180 calendar days, or until August 13, 2002, to regain compliance. However, prior to that time, the Company was delisted according to the above mentioned reasons.

17

Shares traded on the OTC Bulletin Board are not as liquid as those traded on the Nasdaq National market or the Nasdaq SmallCap market.

At February 28, 2003, Lancer had a \$400,000 revolving line of credit with GE Capital Healthcare Financial Services, expiring October 24, 2003. Borrowings are made at prime plus 2.00% (8.0% at February 28, 2003) and are limited to 80% of accounts receivable less than 90 days old with a liquidity factor of 94%. The outstanding balance at February 28, 2003 was \$478 and the unused portion available under the line of credit at February 28, 2003 was \$310,000. The line of credit expires October 24, 2003. The line of credit is collateralized by substantially all the assets of Lancer, including inventories, receivables and equipment. The lending agreement requires that receivables payments be sent to a controlled lockbox. In addition to interest, a management fee of .0425% on the average monthly unused portion available is required. Lancer is not required to maintain compensating balances in connection with this lending agreement. Proceeds from this line cannot be used to support the operations of Biomerica.

Biomerica, Inc. entered into a line of credit agreement on September 12, 2000 with Janet Moore, one of our a shareholders, who also serves as our Chief Financial Officer and Secretary and as a director, whereby the shareholder she will loan to the Company, as needed, up to \$500,000 for working capital needs. The line of credit bears interest at 8%, is secured by Biomerica accounts receivable and inventory and expires September 12, 2003. The unused portion of the line of credit at February 28, 2003, was \$181,750. Additionally, the Company received a \$10,000 unsecured loan from a different shareholder. Such amount is included in shareholder loan in the accompanying financial statements. The Company has no other line of credit available to it.

THE COMPANY MAY FACE INTERRUPTION OF PRODUCTION AND SERVICES DUE TO INCREASED SECURITIES MEASURES IN RESPONSE TO TERRORISM:

Biomerica's and Lancer's business depends on the free flow of products and services through the channels of commerce. Recently, in response to terrorists' activities and threats aimed at the United States, transportation, mail, financial and other services have been slowed or stopped altogether. Further delays or stoppages in transportation, mail, financial or other services could have a material adverse effect on the Company's business, results of operations and financial condition. Furthermore, the Company may experience an increase in operating costs, such as costs for transportation, insurance and security as a result of the

Edgar Filing: BIOMERICA INC - Form 10QSB/A

activities and potential activities. The Company may also experience delays in receiving payments from payers that have been affected by the terrorist activities and potential activities. The U.S. economy in general is being adversely affected by the terrorist activities and potential activities and any economic downturn could adversely impact our results of operations, impair our ability to raise capital or otherwise adversely affect the ability to grow the Company's business.

Item 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

You should read the following factors in conjunction with the factors discussed elsewhere in this and our other filing with the SEC and in materials incorporated by reference in these filing. The following is intended to highlight certain factors that may affect the financial condition and results of operations of Biomerica and are not meant to be an exhaustive discussion of risks that apply to companies such as Biomerica. Like other businesses, Biomerica is susceptible to macroeconomic downturns in the United States or abroad, as were experienced in fiscal year 2002, that may affect the general economic climate and performance of Lancer or its customers. Aside from general macroeconomic downturns, the additional material factors that could affect future financial results include, but are not limited to: Terrorist attacks and the impact of such events; diminished access to raw materials that directly enter into our manufacturing process; shipping labor disruption or other major degradation of the ability to ship our products to end users; inability to successfully control our margins which are affected by many factors including competition and product mix; protracted shutdown of the US border due to an escalation of terrorist or counter terrorist activity; the operating and financial covenants contained in our credit line which could limit our operating flexibility, any changes in our business relationships with international distributors or the economic client they operate in; any event that has a material adverse impact on our foreign manufacturing operations may adversely affect our operations as a whole, failure to manage the future expansion of our business could have a material adverse impact on our foreign manufacturing

operations may adversely affect our operations as a whole, failure to manage the future expansion of our business could have a material adverse affect on our revenues and profitability; possible costs in complying with government regulations and the delays in receiving required regulatory approvals or the enactment of new adverse regulations or regulatory requirements; numerous competitors, some of which have substantially greater financial and other resources than we do; potential claims and litigation brought by patients or dental professionals alleging harm caused by the use of or exposure to our products; quarterly variations in operating results caused by a number of factors, including business and industry conditions and other factors beyond our control. All these factors make it difficult to predict operating results for any particular period.

18

Item 4. PROCEDURES AND CONTROLS

Within the 90 days prior to the date of this report, Biomerica carried out an evaluation, under the supervision and with the participation of Biomerica's management, including the Company's Chief Executive Officer

Edgar Filing: BIOMERICA INC - Form 10QSB/A

and Chief Financial Officer, of the effectiveness of the design and operation of Biomerica's disclosure controls and procedures pursuant to Exchange Act Rule 13a-14. Based upon that evaluation, the Chief Executive Officer and Chief Financial Officer concluded that 's disclosure controls and procedures are effective. There were no significant changes in Biomerica's internal controls or in other factors that could significantly affect these controls subsequent to the date of their evaluation.

POTENTIAL CONSEQUENCES OF ALLERGY IMMUNO TECHNOLOGY, INC.'S FAILURE TO CONDUCT A FORMAL STOCKHOLDER VOTE IN CONNECTION WITH OUR PURCHASE OF ASSETS FROM IT AND ASSUMPTION OF ITS LIABILITIES

During not less than the preceding three years, AIT, a former majority-owned subsidiary of ours, had been unprofitable and, for financial statement reporting purposes, its losses were consolidated into our financial statements. In March of 2002, AIT ceased its clinical testing services. Thereafter, in late April of 2002, we entered into a transaction, pursuant to which, at the end of May of 2002, AIT transferred its remaining assets to us (valued on its financial statements at approximately \$8,000), issued to us approximately 808,500 shares of its restricted common stock (valued as of the date of the transaction at approximately \$19,000), and we assumed its remaining liabilities (recorded on its financial statements at approximately \$27,000) (the "Asset/Liability Transaction"). The Asset/Liability Transaction was approved by our board on April 22, 2002. Approval by our stockholders was not required under Delaware corporate law. We understand that AIT's board approved the Asset/Liability Transaction in April of 2002 and that, rather than calling a formal meeting of AIT's stockholders, our consent to that transaction was deemed to constitute the approval of the holders of a majority of AIT's capital stock, as permitted by Delaware corporate law.

The Company's substantial recurring losses from operations during the preceding years and its lack of readily available capital, other than a line of credit from a stockholder and officer, to help fund operations were the major factors in its decision to stop lending funds to AIT. Both ReadyScript and AIT contributed to the Company's losses. Accordingly, the Company discontinued operations of ReadyScript in May of 2001 and ceased funding of AIT one year later. (See Notes 2 and 13 to the Company's Audited Financial Statements for the year ended May 31, 2002).

At the time of the approval of the Asset/Liability Transaction, our seven directors were Allen Barbieri, David Barrows, Carlos Beharie, M.D., Francis R. Cano, Ph.D., Zackary S. Irani, Janet Moore, and Robert A. Orlando, M.D., Ph.D., three of whom (Mr. Irani, Ms. Moore, and Dr. Orlando) were also directors of AIT. AIT's fourth director at such time was Susan Irani, whom AIT deemed to be an affiliate of ours. Further, at such time, Mr. Irani served as the Chief Executive Officer and Ms. Moore served as the Chief Financial Officer and Secretary of both AIT and us. The Asset/Liability Transaction was negotiated by management common to AIT and us and was approved by all of our directors (including the directors constituting a majority of our board, who did not serve in common with AIT). We were advised that the Asset/Liability Transaction was approved by all of the AIT directors (each of whom also served as one of our directors or was deemed to be an affiliate of ours).

Notwithstanding the approval of the Asset/Liability Transaction by AIT's board and its majority stockholder, AIT may not have provided prompt notice of that approval to all of its stockholders in a manner fully consistent with Delaware corporate law. That failure could have certain potential consequences. Although AIT did not solicit proxies from its stockholders, it also did not file a Schedule 14C with the Securities and Exchange Commission in connection with the approval of the Asset/Liability

Edgar Filing: BIOMERICA INC - Form 10QSB/A

Transaction by its majority stockholder. Further, the potential exists that one of AIT's stockholders could bring a legal action under Delaware state law against AIT either to rescind the Asset/Liability Transaction, or to seek damages against AIT. Because of our status as an affiliate of AIT at the time of the Asset/Liability Transaction, such failure to file a Schedule 14C or a potential action could also name us, our directors, and our officers. As of the date of this amended filing, no action has been filed, and no proceeding has been commenced, against us or any of our directors or officers, and no person or agency has contacted us or our directors or officers announcing an intention to bring any action or to commence any proceeding.

We have been advised by counsel to AIT that, as of the date of this amended filing, no action has been filed, and no proceeding has been commenced, against AIT or any of its directors or officers, and no person or agency has contacted AIT or its directors or officers announcing an intention to bring any action or to commence any proceeding. AIT has informed us that its present attorney has advised it that the likelihood of such an action or proceeding is minimal, the possibility of its success on the merits is remote, and the scope of any potential damages award is nominal for a variety of reasons. For example,

No AIT stockholder or other person with potential standing to sue has announced dissatisfaction with the Asset/Liability Transaction, although it was announced publicly in June of 2002.

The assets that were the subject of the Asset/Liability Transaction had historically yielded only unprofitable operations, which operations had ceased prior to the approval of the Asset/Liability Transaction, as well as the closing of that transaction.

The value of the assets that were the subject of the Asset/Liability Transaction was small and less than the amount of liabilities that we concurrently assumed; thus, any award the compensation due to any potential plaintiffs upon a successful claim would be correspondingly small.

Any potential liability under such a claim would be incapable of precise determination because the measure of damages under such a claim would depend upon a subjective valuation of the assets and liabilities that were the subject of the Asset/Liability Transaction.

We do not believe that such an action is probable, nor that a liability for such an action, if any, could be estimated. Accordingly, we have not accrued a liability in the accompanying consolidated financial statements related to the aforementioned matter.

PART II. OTHER INFORMATION

Item 1. LEGAL PROCEEDINGS. Inapplicable.

Item 2. CHANGES IN SECURITIES AND USE OF PROCEEDS. The following shares of restricted common stock were issued during the nine months ended February 28, 2003:

Date	Title	Amount	Class or Persons Sold to	Price Per Share	Total
9/02/02	common	87,778	insiders & qualified investors	\$.045	\$39,500

The exemption relied upon for the issuance of the unregistered shares was that the shares were issued to accredited investors

Edgar Filing: BIOMERICA INC - Form 10QSB/A

within the meaning of Securities and Exchange Commission Rule 501, Regulation D.

- Item 3. DEFAULTS UPON SENIOR SECURITIES. Inapplicable.
- Item 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS. Inapplicable.
- Item 5. EXHIBITS AND REPORTS ON FORM 8-K. A report on Form 8-K was filed with the Securities and Exchange Commission on June 6, 2002.
- Item 6. EXHIBITS AND REPORTS ON FORM 8-K. A report on Form 8-K was filed with the Securities and Exchange Commission on June 6, 2002.
- (a) Exhibits
- 99.1 Certifications of Chief Executive Officer and Chief Financial Officer pursuant To 18 U.S.C., Section 1350, as adopted pursuant to Section 302 and 906 of the Sarbanes-Oxley Act of 2002.

19

SIGNATURES

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has fully caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Date: June 5, 2003

BIOMERICA, INC.
By: /S/ Zackary S. Irani

Zackary S. Irani
Chief Executive Officer

20

STATEMENT PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
BY PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER REGARDING
FACTS AND CIRCUMSTANCES RELATING TO EXCHANGE ACT FILINGS

I, Janet Moore, certify that:

1. I have reviewed this amended quarterly report on Form 10-QSB/A of Biomerica, Inc.
2. Based on my knowledge, this amended quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this amended quarterly report;
3. Based on my knowledge, the financial statements, and other financial information included in this amended quarterly report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the period presented in this amended

Edgar Filing: BIOMERICA INC - Form 10QSB/A

quarterly report;

4. The registrant's other certifying officer and I are responsible for establishing and Maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-14 and 15d-14 for the registrant and we have:

a) designed such disclosure controls and procedures to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this amended quarterly report is being prepared;

b) evaluated the effectiveness of the registrant's disclosure controls and procedures as of a date within 90 days prior to the filing date of this amended quarterly report (the "Evaluation Date"); and; c) presented in this amended quarterly report our conclusions about the effectiveness of the disclosure controls and procedures based on our evaluation as of the Evaluation Date;

5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent function):

a) all significant deficiencies in the design or operation of internal controls which could adversely affect the registrant's ability to record, process, summarize and report financial data and have identified for the registrant's auditors any material weaknesses in internal controls; and

b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal controls; and

6. The registrant's other certifying officer and I have indicated in this amended quarterly report whether or not there were significant changes in internal controls or in other factors that could significantly affect internal controls subsequent to the date of our most recent evaluation, including any corrective actions with regard to significant deficiencies and material weaknesses.

Date: June 5, 2003

/s/ Janet Moore
Chief Financial Officer

STATEMENT PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 BY
PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER REGARDING FACTS
AND CIRCUMSTANCES RELATING TO EXCHANGE ACT FILINGS

I, Zackary Irani, certify that:

1. I have reviewed this amended quarterly report on Form 10-QSB of Biomerica, Inc.

2. Based on my knowledge, this amended quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this amended quarterly report;

Edgar Filing: BIOMERICA INC - Form 10QSB/A

3. Based on my knowledge, the financial statements, and other financial information included in this quarterly report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the period presented in this amended quarterly report;

4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-14 and 15d-14) for the registrant and we have:

a) designed such disclosure controls and procedures to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this amended quarterly report is being prepared;

b) evaluated the effectiveness of the registrant's disclosure controls and procedures as of a date within 90 days prior to the filing date of this amended quarterly report (the "Evaluation Date"); and; c) presented in this amended quarterly report our conclusions about the effectiveness of the disclosure controls and procedures based on our evaluation as of the Evaluation Date;

5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent function):

a) all significant deficiencies in the design or operation of internal controls which could adversely affect the registrant's ability to record, process, summarize and report financial data and have identified for the registrant's auditors any material weaknesses in internal controls; and

b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal controls; and

6. The registrant's other certifying officer and I have indicated in this amended quarterly report whether or not there were significant changes in internal controls or in other factors that could significantly affect internal controls subsequent to the date of our most recent evaluation, including any corrective actions with regard to significant deficiencies and material weaknesses.

Date: June 5, 2003

/s/ Zackary S. Irani
Chief Executive Officer